131 related articles for article (PubMed ID: 38561927)
1. Assessing efficacy in non-inferiority trials with non-adherence to interventions: Are intention-to-treat and per-protocol analyses fit for purpose?
Dodd M; Carpenter J; Thompson JA; Williamson E; Fielding K; Elbourne D
Stat Med; 2024 May; 43(12):2314-2331. PubMed ID: 38561927
[TBL] [Abstract][Full Text] [Related]
2. Intention-to-treat analysis may be more conservative than per protocol analysis in antibiotic non-inferiority trials: a systematic review.
Bai AD; Komorowski AS; Lo CKL; Tandon P; Li XX; Mokashi V; Cvetkovic A; Findlater A; Liang L; Tomlinson G; Loeb M; Mertz D;
BMC Med Res Methodol; 2021 Apr; 21(1):75. PubMed ID: 33874894
[TBL] [Abstract][Full Text] [Related]
3. The use of randomisation-based efficacy estimators in non-inferiority trials.
Gillespie D; Farewell D; Barrett-Lee P; Casbard A; Hawthorne AB; Hurt C; Murray N; Probert C; Stenson R; Hood K
Trials; 2017 Mar; 18(1):117. PubMed ID: 28274254
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the results of intent-to-treat, per-protocol, and g-estimation in the presence of non-random treatment changes in a time-to-event non-inferiority trial.
Matsuyama Y
Stat Med; 2010 Sep; 29(20):2107-16. PubMed ID: 20552682
[TBL] [Abstract][Full Text] [Related]
5. Choosing the analysis population in non-inferiority studies: per protocol or intent-to-treat.
Matilde Sanchez M; Chen X
Stat Med; 2006 Apr; 25(7):1169-81. PubMed ID: 16397861
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Treatment crossovers in time-to-event non-inferiority randomised trials of radiotherapy in patients with breast cancer.
Parpia S; Julian JA; Thabane L; Gu C; Whelan TJ; Levine MN
BMJ Open; 2014 Oct; 4(10):e006531. PubMed ID: 25344487
[TBL] [Abstract][Full Text] [Related]
8. Statistical considerations in the design and analysis of non-inferiority trials with binary endpoints in the presence of non-adherence: a simulation study.
Mo Y; Lim C; Mukaka M; Cooper BS
Wellcome Open Res; 2019; 4():207. PubMed ID: 32420455
[TBL] [Abstract][Full Text] [Related]
9. Digital adherence technology for tuberculosis treatment supervision: A stepped-wedge cluster-randomized trial in Uganda.
Cattamanchi A; Crowder R; Kityamuwesi A; Kiwanuka N; Lamunu M; Namale C; Tinka LK; Nakate AS; Ggita J; Turimumahoro P; Babirye D; Oyuku D; Berger C; Tucker A; Patel D; Sammann A; Turyahabwe S; Dowdy D; Katamba A
PLoS Med; 2021 May; 18(5):e1003628. PubMed ID: 33956802
[TBL] [Abstract][Full Text] [Related]
10. Statistical methods for non-adherence in non-inferiority trials: useful and used? A systematic review.
Dodd M; Fielding K; Carpenter JR; Thompson JA; Elbourne D
BMJ Open; 2022 Jan; 12(1):e052656. PubMed ID: 35022173
[TBL] [Abstract][Full Text] [Related]
11. Estimating treatment effects in randomised controlled trials with non-compliance: a simulation study.
Ye C; Beyene J; Browne G; Thabane L
BMJ Open; 2014 Jun; 4(6):e005362. PubMed ID: 24939814
[TBL] [Abstract][Full Text] [Related]
12. Intention-to-treat and transparency of related practices in randomized, controlled trials of anti-infectives.
Beckett RD; Loeser KC; Bowman KR; Towne TG
BMC Med Res Methodol; 2016 Aug; 16(1):106. PubMed ID: 27557676
[TBL] [Abstract][Full Text] [Related]
13. Correcting for non-compliance in randomized non-inferiority trials with active and placebo control using structural models.
Wu Y; Zhao L; Hou Y; Li K; Zhou X
Stat Med; 2015 Mar; 34(6):950-65. PubMed ID: 25534903
[TBL] [Abstract][Full Text] [Related]
14. Per-Protocol analyses produced larger treatment effect sizes than intention to treat: a meta-epidemiological study.
Mostazir M; Taylor G; Henley WE; Watkins ER; Taylor RS
J Clin Epidemiol; 2021 Oct; 138():12-21. PubMed ID: 34161805
[TBL] [Abstract][Full Text] [Related]
15. Methodological and reporting quality of non-inferiority randomized controlled trials comparing antifungal therapies: a systematic review.
Komorowski AS; Bai AD; Cvetkovic A; Mourad O; Lo CKL; Li XX; Mokashi V; Findlater A; Duncan DB; Fuller C; Yamamura D; Mertz D;
Clin Microbiol Infect; 2022 May; 28(5):640-648. PubMed ID: 34763055
[TBL] [Abstract][Full Text] [Related]
16. Intention-to-treat versus as-treated versus per-protocol approaches to analysis.
Ahn E; Kang H
Korean J Anesthesiol; 2023 Dec; 76(6):531-539. PubMed ID: 38031328
[TBL] [Abstract][Full Text] [Related]
17. Dichotomizing partial compliance and increased participant burden in factorial designs: the performance of four noncompliance methods.
Merrill PD; McClure LA
Trials; 2015 Nov; 16():523. PubMed ID: 26573840
[TBL] [Abstract][Full Text] [Related]
18. Interval-cohort designs and bias in the estimation of per-protocol effects: a simulation study.
Young JG; Vatsa R; Murray EJ; Hernán MA
Trials; 2019 Sep; 20(1):552. PubMed ID: 31488202
[TBL] [Abstract][Full Text] [Related]
19. Adjusting for adherence in randomized trials when adherence is measured as a continuous variable: An application to the Lipid Research Clinics Coronary Primary Prevention Trial.
Wanis KN; Madenci AL; Hernán MA; Murray EJ
Clin Trials; 2020 Oct; 17(5):570-575. PubMed ID: 32414298
[TBL] [Abstract][Full Text] [Related]
20. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
